Total Funding
59
3
Total FundingPost-IPO Debt raised
Growth Score
-4 pts
Heat Score
-4 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
1664328
Avanir Pharmaceuticals is a biopharmaceutical company focused on providing medicines to patients with central nervous system disorders.
Acquired by 
Otsuka Holdings
David H. Katz: Founder & CEO
Hieu Tran: Lean Six Sigma Black Belt Consultant, Enterprise PMOPast Role: Vocado, Vice President of IT and Corporate Compliance
About the Company
Avanir Pharmaceuticals is a biopharmaceutical company focused on bringing innovative medicines to patients with central nervous system disorders of high unmet medical need. As part of their commitment, they have extensively invested in their pipeline and are dedicated to advancing medicines that can substantially improve the lives of patients and
their loved ones.
